Laddar...
Identifying and Validating a Combined mRNA and MicroRNA Signature in Response to Imatinib Treatment in a Chronic Myeloid Leukemia Cell Line
Imatinib, a targeted tyrosine kinase inhibitor, is the gold standard for managing chronic myeloid leukemia (CML). Despite its wide application, imatinib resistance occurs in 20–30% of individuals with CML. Multiple potential biomarkers have been identified to predict imatinib response; however, the...
Sparad:
| I publikationen: | PLoS One |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Public Library of Science
2014
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4266614/ https://ncbi.nlm.nih.gov/pubmed/25506832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0115003 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|